NEW YORK (GenomeWeb News) – Ventana Medical Systems today announced it is co-exclusively sublicensing certain patents and patents applications from Gen-Probe for the worldwide in vitro diagnostic rights to measure ERG protein expression by immunohistochemistry in prostate tissue.

Ventana, a Roche company, said that the license complements its existing worldwide co-exclusive sublicense under certain patents and patent applications for in situ hybridization for measuring ETS gene rearrangements, such as ERG gene rearrangements in tissue.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

An Australian study of personalized medicine has run into problems as it recruits patients.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.